DNA Methylation Signatures as Early Epigenetic Biomarkers of Metabolic Risk in Obesity
Obesity is a multifactorial metabolic disorder influenced by genetic, environmental, and lifestyle factors, raising the chance of developing type 2 diabetes (T2D), cardiovascular diseases, and metabolic syndrome. DNA methylation, in particular, is one of the epigenetic mechanisms that play an important role in linking environmental exposures to changed expression of genes and metabolic dysfunction. This mini‑review highlights DNA methylation's potential signatures as early biomarkers of metabolic risk in obesity. DNA methylation is the addition of methyl groups to cytosine residues, altering gene expression without changing the DNA sequence. Altered methylation patterns in genes such as Leptin (LEP), Adiponectin (ADIPOQ), Proopiomelanocortin (POMC), Neuropeptide Y (NPY), Peroxisome Gamma Coactivator 1‑Alpha (PGC1A), and Hypoxia Inducible Factor 3 Subunit Alpha (HIF3A) have been linked to insulin resistance, obesity, energy imbalance, and inflammation. These changes may help identify individuals at risk of developing obesity‑related metabolic complications. Furthermore, DNA methylation is potentially reversible and can be influenced by dietary modifications, physical activity, and weight reduction, making it a promising target for preventive and personalised interventions. However, tissue‑specific variations and differences in study populations remain challenges. Additional long‑term research is needed to validate reliable DNA methylation signatures and establish their clinical utility in early metabolic risk prediction and personalised obesity management.
Authors
- Asha Prabhu
- Chethana Y K
- Mamatha B V
- Nishitha Clamenteen Salins
- Chaithra D
Publication Details
- Journal
- Indo-American Journal of Life Sciences and Biotechnology
- Published
- 2026-11-20
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.00